

Environmental and Social Data Sheet

Overview

Project Name:	Advanced Drugs Manufacturing (Midcap Program Loan)
Project Number:	2017-0327
Country:	Italy
Project Description:	The project concerns the development and production of anticancer drugs with high potency for the pharmaceutical industry and R&D related to the supply of clinical development and formulation services to European SMEs over the period 2017-2019.
EIA required:	no
Project included in Carbon Footprint Exercise:	no

Environmental and Social Assessment

Environmental Assessment

An EIA as foreseen under Directive 2014/52/EU amending the EIA Directive 2011/92/EU is not required for the type of projects carried out by the Promoter.

Other Environmental and Social Aspects

The Promoter is aligned to labour standards and is active in training staff to guarantee best measures of protection against safety and professional health risks. Waste management is also handled in conformity to national laws.

On a general note, this project will address an unmet medical need by provisioning more efficient and cost effective oncological drugs to the population thus benefiting the health status of the population and is seen as an element of social cohesion.

Conclusions and Recommendations

The R&D activities and related CAPEX in the investment plan are conceived to have an impact on the availability of the latest generation anti-cancer drugs needed by providing new formulations, manufacturing technologies and services.

In light of the above, the overall environmental and social rating of the project is therefore considered acceptable with no or minor negative residual impacts and eligible for the Bank's financing.